Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products
Aleafia Health has secured a Health Canada Research Licence for its cannabis product manufacturing centre in Paris, Ontario, enabling human sensory analysis and palatability trials. This regulatory breakthrough complements the company's ongoing innovation strategy in cannabis products. CEO Geoffrey Benic emphasized the importance of product evaluation practices used in the food industry. Aleafia is developing new product formats, including dried flower, edibles, and extracts, aiming for consistent sensory assessments during development.
- Secured Health Canada Research Licence for product evaluation.
- Strengthening product innovation strategy through human sensory analysis.
- Developing a diverse portfolio of cannabis products.
- None.
TORONTO, May 03, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”), a global leader in cannabis wellness products and services, has secured a Health Canada Research Licence for its cannabis product manufacturing and innovation centre in Paris, Ont. The licence allows the Company to conduct human sensory analysis and palatability trials, evaluating the taste, touch, smell and sight of its growing portfolio of differentiated medical and consumer cannabis products.
“As we continue to bring highly innovative formats to market, our development team will now employ an important best practice of product evaluation used in the food and beverage industries,” said Aleafia Health CEO Geoffrey Benic. “Through a first to market product strategy, we’ve developed a track record for product innovation that will only be strengthened by this regulatory breakthrough.”
Aleafia Health is currently developing a number of new product formats and line extensions to complement its existing cannabis portfolio of dried flower, edibles, sublingual strips, soft gels, extracts, and vape cartridges. The Company intends to conduct sensory assessment studies consistently during product development, allowing human panels to evaluate objective product characteristics, and evaluate preference between comparable products.
For Investor & Media Relations:
Nicholas Bergamini, VP Investor Relations
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.
Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
FAQ
What is the significance of the Health Canada Research Licence for ALEAF?
What types of products is Aleafia Health developing following the license acquisition?
How does Aleafia Health plan to utilize the new sensory analysis capabilities?
Who is the CEO of Aleafia Health and what did he say about the new license?
Where is Aleafia Health's cannabis product manufacturing and innovation centre located?
